Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present is a research paper published in Biomolecules (2022). On theSindex it has a DataRank of 0.581. It has been cited 47 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.581
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Clinical and Translational Science Collaborative of Cleveland
Grant: UL1TR002548
Clinical and Translational Science Collaborative of Cleveland
Grant: 1R01GM100887-01
Investigating the structural assembly of RNR multimers
Clinical and Translational Science Collaborative of Cleveland
Grant: R01 CA212600
Clinical and Translational Science Collaborative of Cleveland
Grant: R37CA227865-01A1
NCI NIH HHS
Grant: R37 CA227865
National Institutes of Health
Grant: 3UL1TR002548-03S1
Clinical and Translational Science Collaborative of Cleveland
National Institutes of Health
Grant: 5R37CA227865-07
Targeting pancreatic cancer's metabolic addiction to HuR
National Institutes of Health
Grant: 3R01CA212600-03S1
Targeting HuR to improve a synthetic lethal therapy for pancreatic cancer
FWCI
2.78
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor
Additional file 1 of Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor